Bristol-Myers Squibb Company (BMY)
Bristol Myers Squibb Warns Near-Term Impact Due To Generics On 2025 Sales Forecast, Outlines $2 Billion In Additional Cost Cuts
On Thursday, Bristol Myers Squibb & Co BMY posted fourth-quarter revenues of $12.34 billion, beating the consensus of $11.57 billion.
Bristol Myers Squibb plans $2 billion in cost cuts by 2027, issues weak guidance
Bristol Myers Squibb said it will slash $2 billion in costs by the end of 2027, expanding its ongoing cost savings effort to chart a path toward long-term growth. The company also issued a full-year 2025 guidance that fell short of Wall Street's expectations, as some of the company's older drugs face competition from cheaper generics.
Trade Tracker: Josh Brown buys Bristol-Myers
Josh Brown, CEO of Ritholtz Wealth Management, joins CNBC's "Halftime Report" to explain why he's buying Bristol-Myers at these levels.
BMY Gets Positive CHMP Opinion for Opdivo, Yervoy Combo and Breyanzi
The CHMP recommends approval of Bristol Myers' Opdivo plus Yervoy for the first-line treatment of hepatocellular carcinoma and Breyanzi for relapsed or refractory follicular lymphoma.
Should Bristol Myers Stock Be in Your Portfolio Pre-Q4 Earnings?
BMY is looking to turn its business around, banking on the strong uptake of new drugs. The recent spate of positive regulatory updates also bodes well for the stock.
What Analyst Projections for Key Metrics Reveal About Bristol Myers (BMY) Q4 Earnings
Besides Wall Street's top -and-bottom-line estimates for Bristol Myers (BMY), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2024.
2 High-Yield Dividend Stocks to Hold Through 2025 and Beyond
If there were an official hierarchy of qualities that dividend seekers should consider before investing in a stock, a company's underlying business would almost certainly come ahead of its yield. However, the two aren't mutually exclusive.
Is Big Pharma About To Win? Goldman Sachs Weighs In On 340B And Medicaid Shifts
Medicaid funding, totaling approximately $900 billion per year and serving around 72 million participants, and the 340B program are key focus areas for potential healthcare reforms.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Will Bristol Myers (BMY) Beat Estimates Again in Its Next Earnings Report?
Bristol Myers (BMY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Bristol Myers Squibb (BMY) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Bristol Myers (BMY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
10 Undervalued Dividend Growth Stocks: January 2025
I rank a selection of undervalued dividend growth stocks in Dividend Radar and present the ten top-ranked stocks for consideration. I use two valuation screens, one based on my fair value estimate, and another comparing each stock's forward dividend yield with its 5-year average dividend yield. To rank stocks, I do a quality assessment and sort candidates by quality scores, breaking ties with additional metrics.
